Molnupiravir and Its Active Form, EIDD-1931, Show Potent Antiviral Activity against Enterovirus Infections In Vitro and In Vivo

Yuexiang Li, Miao Liu, Yunzheng Yan, Zhuang Wang, Qingsong Dai, Xiaotong Yang, Xiaojia Guo, Wei Li, Xingjuan Chen, Ruiyuan Cao, Wu ZhongViruses 2022 · DOI

TL;DR

This study investigates the antiviral potential of molnupiravir (EIDD-2801) and its active metabolite, EIDD-1931, against enteroviruses, a group of viruses responsible for significant childhood illnesses. The research demonstrates that both compounds exhibit potent in vitro and in vivo antiviral activity against Enterovirus A71 (EV-A71) and a broad spectrum of other enteroviruses, suggesting their potential as a new therapeutic option.

What Problem Does This Paper Address?

Enteroviruses are a diverse group of viruses that cause a range of illnesses, from mild hand, foot, and mouth disease (HFMD) to severe neurological complications like meningitis and encephalitis, particularly in infants and young children. Despite the global burden of these infections, there is a significant lack of specific antiviral drugs approved for their treatment. Current prevention strategies rely heavily on vaccines, which are often serotype-specific and may not offer protection against the vast array of enteroviral strains. This unmet medical need highlights the critical importance of developing broad-spectrum antiviral agents that can combat a wide range of enterovirus infections.

Methods

The researchers employed a multi-pronged approach to evaluate the antiviral efficacy of EIDD-1931 and EIDD-2801:

  • In Vitro Antiviral Assays:
    • Cytopathic Effect (CPE) Protection Assay: This standard method assesses the ability of compounds to prevent virus-induced cell damage. Different cell lines (RD, Vero, Huh7) were infected with EV-A71, and the compounds were added at various concentrations. Cell viability was measured to determine the half-maximal effective concentration (EC50) and half-cytotoxic concentration (CC50).
  • Viral RNA and Particle Yield Assays: Quantitative real-time PCR (qRT-PCR) was used to measure viral RNA levels in infected cells, while TCID50 assays quantified infectious viral particle production in the supernatant.
  • Immunofluorescence Assay (IFA) and Western Blot: These techniques were used to detect and quantify viral capsid protein (VP1) expression, a key indicator of viral replication.
  • Time-of-Drug-Addition Assay: This assay helped pinpoint the stage of the viral life cycle at which EIDD-1931 exerts its antiviral effect. By adding the drug at different time points relative to viral infection, researchers could determine if it acted during entry, replication, or release.
  • In Vivo Antiviral Assays:
    • Murine Model of Lethal EV-A71 Infection: One-day-old ICR suckling mice were used to model severe EV-A71 infection. Mice were infected with a lethal dose of EV-A71, and then treated with EIDD-1931 or EIDD-2801 via intraperitoneal injection. Survival rates, body weight changes, and viral loads in various tissues (brain, heart, intestine, liver, muscle, lung) were monitored.
  • Pharmacokinetic Analysis: While not explicitly detailed as a separate experiment, the paper mentions that pharmacokinetic analysis indicated plasma drug concentrations overwhelmed the EC50 for enteroviruses, a crucial factor for clinical potential.

Datasets

The study utilized established cell lines: RD (Human Rhabdomyosarcoma), Vero (African green monkey kidney), and Huh7 (human hepatocellular carcinoma). Various enterovirus strains were used, including EV-A71 (H strain and AH08/06 strain), EV-D68 (STL-2014-12 strain), CV-A6 (TW-2007-00141 strain), CV-A16 (190-D1 strain), and CV-B3 (Nancy strain). These viruses were obtained from standard cell culture collections (ATCC, National Infrastructure of Cell Line Resource) or provided by collaborators. No new benchmark datasets were introduced.

Key Insights and Ideas

  • Molnupiravir's Broad-Spectrum Potential: The most significant insight is that molnupiravir and its active form, EIDD-1931, are not just effective against SARS-CoV-2 but also demonstrate potent antiviral activity against a wide range of enteroviruses. This broadens the potential therapeutic applications of these drugs considerably.
  • EIDD-1931 is More Potent In Vitro: While both compounds showed activity, EIDD-1931 consistently demonstrated lower EC50 values (higher potency) compared to its prodrug, EIDD-2801, across different cell lines and enterovirus strains. This aligns with the understanding that EIDD-1931 is the active metabolite.
  • Post-Entry Mechanism of Action: The time-of-drug-addition assay strongly suggests that EIDD-1931 acts at the post-entry stage of the viral life cycle, consistent with its known mechanism of inducing lethal mutagenesis in viral RNA.
  • In Vivo Efficacy in a Neonatal Model: The study successfully demonstrated that EIDD-1931 and EIDD-2801 can protect vulnerable 1-day-old mice from lethal EV-A71 challenge, significantly reducing viral loads in multiple organs. This is particularly relevant given that enteroviruses disproportionately affect infants and young children.
  • Favorable Pharmacokinetics for Enterovirus Treatment: The reported plasma drug concentrations exceeding the EC50 for enteroviruses in vivo are a critical finding, suggesting that therapeutic levels can be achieved to combat these infections.

Key Results

  • In Vitro Antiviral Activity:
    • EIDD-1931 showed EC50 values ranging from 2.79 to 15.72 µM against various enteroviruses in different cell lines.
  • EIDD-2801 exhibited EC50 values ranging from 30.29 to >100 µM, indicating lower potency than EIDD-1931.
  • EIDD-1931 significantly reduced EV-A71 progeny virus production and VP1 protein expression at non-cytotoxic concentrations.
  • EIDD-2801 also inhibited viral replication and VP1 expression, though generally at higher concentrations than EIDD-1931.
  • In Vivo Antiviral Activity:
    • Intraperitoneal administration of EIDD-1931 (200 and 66.6 mg/kg) resulted in 100% survival in 1-day-old mice challenged with lethal EV-A71.
  • EIDD-2801 also conferred significant survival benefits, with 100% and 67% survival at the highest doses.
  • Treatment with both compounds significantly reduced viral RNA loads in the brain, heart, intestine, liver, muscle, and lung of infected mice.
  • Broad-Spectrum Activity: EIDD-1931 demonstrated inhibitory activity against EV-A71, EV-D68, CV-A16, and CV-B3, with EC50 values below 20 µM. EIDD-2801 showed activity against most strains but had limited or no activity against EV-D68, CV-A16, and CV-A6.

Limitations and Future Work

  • Human Bioavailability Concerns: While EIDD-2801 was designed to improve oral bioavailability, the paper acknowledges that previous studies have indicated low plasma concentrations in non-human primates, suggesting potential challenges for human use, especially in children. Further pharmacokinetic studies in relevant models are needed.
  • Mechanism of Action Nuances: While the time-of-drug-addition assay points to a post-entry mechanism, the exact molecular events (e.g., direct inhibition of RdRp vs. other post-entry processes) require further investigation, potentially through replicon experiments.
  • Pediatric Safety and Efficacy: The paper notes that molnupiravir is currently approved only for adults over 18, while enteroviruses primarily affect children. Therefore, extensive studies on the safety and efficacy of molnupiravir in pediatric populations are crucial before clinical application for enterovirus infections.
  • Resistance Development: The potential for enteroviruses to develop resistance to these drugs was not explored in this study and warrants future investigation.
  • Clinical Translation: The study provides strong preclinical evidence, but the ultimate success of EIDD-2801 as a treatment for enterovirus infections will depend on successful clinical trials.

Summary updated

Abstract

Enterovirus infections can cause hand, foot, and mouth disease (HFDM), aseptic meningitis, encephalitis, myocarditis, and acute flaccid myelitis, leading to death of infants and young children. However, no specific antiviral drug is currently available for the treatment of this type of infection. The Unites States and United Kingdom health authorities recently approved a new antiviral drug, molnupiravir, for the treatment of COVID-19. In this study, we reported that molnupiravir (EIDD-2801) and its active form, EIDD-1931, have broad-spectrum anti-enterovirus potential. Our data showed that EIDD-1931 could significantly reduce the production of EV-A71 progeny virus and the expression of EV-A71 viral protein at non-cytotoxic concentrations. The results of the time-of-addition assay suggest that EIDD-1931 acts at the post-entry step, which is in accordance with its antiviral mechanism. The intraperitoneal administration of EIDD-1931 and EIDD-2801 protected 1-day-old ICR suckling mice from lethal EV-A71 challenge by reducing the viral load in various tissues of the infected mice. The pharmacokinetics analysis indicated that the plasma drug concentration overwhelmed the EC<sub>50</sub> for enteroviruses, suggesting the clinical potential of molnupiravir against enteroviruses. Thus, molnupiravir along with its active form, EIDD-1931, may be a promising drug candidate against enterovirus infections.
BibTeX
@inproceedings{li2022molnupiravir,
  author = {Yuexiang Li and Miao Liu and Yunzheng Yan and Zhuang Wang and Qingsong Dai and Xiaotong Yang and Xiaojia Guo and Wei Li and Xingjuan Chen and Ruiyuan Cao and Wu Zhong},
  title = {{Molnupiravir and Its Active Form, EIDD-1931, Show Potent Antiviral Activity against Enterovirus Infections In Vitro and In Vivo}},
  booktitle = {Viruses},
  year = {2022},
  doi = {10.3390/v14061142},
}
Figure